Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 216-885-3 | CAS number: 1689-99-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 13 Jan - 7 Feb 1992
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 992
- Report date:
- 1992
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
- Version / remarks:
- adopted 1981
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 82-2 (Repeated Dose Dermal Toxicity -21/28 Days)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2,6-dibromo-4-cyanophenyl octanoate
- EC Number:
- 216-885-3
- EC Name:
- 2,6-dibromo-4-cyanophenyl octanoate
- Cas Number:
- 1689-99-2
- Molecular formula:
- C15H17Br2NO2
- IUPAC Name:
- 2,6-dibromo-4-cyanophenyl octanoate
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Hazleton Research Products Inc, Michigan, USA
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 17 - 18 weeks
- Weight at study initiation: 2.447 - 2.999 kg (males), 2.457 - 2.840 kg (females)
- Fasting period before study: no
- Housing: individually in stainless steel, screen-bottom cages.
- Diet: Certified High Fiber Rabbit Chow5 #5325 (Purina Mills, Inc.), ca 180 g/day and animal
- Water: tap water, ad libitum
- Acclimation period: 26 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 23
- Humidity (%): 30 - 70
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 13 Jan 1992 To: 7 Feb 1992
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Remarks:
- the test material was moistened with deionized water (2.0 mL)
- Details on exposure:
- TEST SITE
- Area of exposure: dorsal trunk
- % coverage: ca. 10%
- Type of wrap if used: gauze patch, fixed with Coban self-adhesive wrap and secured with elastic tape
- Time intervals for shavings or clippings: before initiation of treatment and as needed thereafter
REMOVAL OF TEST SUBSTANCE
- Washing (if done): the test site was wiped with a clean towel moistened with tap water
- Time after start of exposure: 6 h
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): the appropriate amount of the test material was spread on a gauze patch, moistened with 2.0 mL of deionized water and applied to the skin
- For solids, paste formed: no
USE OF RESTRAINERS FOR PREVENTING INGESTION: yes (flexible plastic collar) - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Dose analysis was not done because the test material was applied neat. Homogeneity, stability, and dose confirmation analyses were the responsibility of the Sponsor.
- Duration of treatment / exposure:
- 6 h per treatment
The treatment period was 3 weeks - Frequency of treatment:
- daily, 5 days/week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 30 mg/kg bw/day
- Dose / conc.:
- 300 mg/kg bw/day
- Dose / conc.:
- 1 000 mg/kg bw/day
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Positive control:
- No
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: The animals were observed for mortality and moribundity twice daily. Once daily, the animals were removed from the cage and examined for signs of toxicity.
DETAILED CLINICAL OBSERVATIONS: No
DERMAL IRRITATION: Yes
- Time schedule for examinations: immediately before each application of the test or control material (except on Day 1) and on the day of necropsy.
BODY WEIGHT: Yes
- Time schedule for examinations: on the first day of treatment (Day 1), weekly thereafter, and at necropsy.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: prior to study start (Week -2) and before scheduled necropsy (Week 4)
- Anesthetic used for blood collection: No
- Animals fasted: No
- How many animals: all animals of all dose groups
- Parameters checked: Red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, white blood cell count, differential blood cell count and blood cell morphology.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: pre study and before scheduled necropsy
- Animals fasted: No
- How many animals:
- Parameters checked: Glucose, urea nitrogen, creatinine, total protein, albumin, globulin, total bilirubin, cholesterol, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, calcium, inorganic phosphorous, sodium, potassium and chloride.
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- After 3 weeks of treatment, all animals were anesthetized with sodium pentobarbital, weighed, exsanguinated, and necropsied.
GROSS PATHOLOGY: Yes
The necropsy of all animals included macroscopic examination of the external surface of the body; all orifices; the cranial cavity; the external surfaces of the brain and spinal cord; the nasal cavity and paranasal sinuses; and the abdominal, thoracic, and pelvic cavities and viscera. Cut surfaces of the brain and spinal cord were examined when tissues were trimmed.
Organs weighed (paired organs weighed separatly): Adrenals, brain, kidneys, liver, ovaries, and testes.
HISTOPATHOLOGY: Yes
- fixed tissues: adrenals, aorta, brain, cecum, colon, duodenum, epididymides, esophagus, eyes, femur with bone marrow (with articular surface), gall bladder, heart, ileum, jejunum, kidneys, lacrimal gland, lesions, liver, lungs, lymph nodes (mesenteric), mammary gland, muscle (thigh), ovaries, pancreas, pituitary, prostate, rectum, salivary gland (submandibular), sciatic nerve, seminal vesicle, skin (treated and untreated), spinal cord (cervical, thoracic and lumbar regions), spleen, sternum with bone marrow, stomach, testes, thymus, thyroids (and parathyroids), trachea, urinary bladder and uterus.
Tissues were fixed in 10% phosphate-buffered formalin. The eyes were preserved in Zenker's solution.
- embedding media: paraffin wax
- staining: hematoxylin and eosin
- animals investigated: control and high-dose animals - Other examinations:
- Bone marrow smears were taken from the sternum at scheduled sacrifice but not examined.
- Statistics:
- Levene's test was done to test for variance homogeneity. In the case of heterogeneity of variance at p ≤ 0.05, transformations were used to stabilize the variance.
Analysis of variance (ANOVA) was done on the homogeneous or transformed data. If the ANOVA was significant, Dunnett's t-test was used for pairwise comparisons between treated and control groups.
One-way ANOVA was used to analyze initial body weights, cumulative body weight gains, food consumption, clinical chemistry and hematology values (except red blood cell morphology), organ weights, organ-to-body weight percentages, and organ-to-brain weight ratios.
One-way analysis of covariance (ANCOVA) was used to analyze body weights, with initial body weights as the covariate. Although Levene's test for variance homogeneity was done (see above), no transformations were used because covariance adjustment removes extraneous heterogeneity. If the ANCOVA was significant, Dunnett's t-test was used for pairwise comparisons between treated and control groups.
Group comparisons were evaluated at the 5.0% two-tailed probability level.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no test material-related observations during the study period.
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- - 0 mg/kg bw/day: slight erythema (2/10 males, 1/10 females)
- 30 mg/kg bw/day: slight erythema (5/10 males, 1/10 females)
- 300 mg/kg bw/day: slight (10/10 males, 8/10 females) to moderate erythema (1/10 males) and slight desquamation (4/10 males, 4/10 females) and edema (1/10 females)
- 1000 mg/kg bw/day: slight (9/10 males, 10/10 females) to moderate erythema (1/10 males, 1/10 females), slight desquamation (8/10 males, 6/10 females), moderate desquamation (1/10 males), slight fissuring (5/10 males, 3/10 females), moderate fissuring (1/10 males), slight edema (1/10 males, 4/10 females), moderate edema (1/10 males, 2/10 females) and slight atonia (1/10 males)
The observations did not increase in severity during treatment.
Summarized results can be found in Attachment 1 in the attached background material. - Mortality:
- no mortality observed
- Description (incidence):
- All animals survived to scheduled sacrifice.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No differences were observed regarding body weight and cumulative body weight gains between control and treatment groups.
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no statistically significant differences in food consumption for females. A significant increase in food consumption was present in Week 3 for males given 30 mg/kg bw/day; however, this difference was not considered to be toxicologically significant, since there was no dose dependency.
Summarized results can be found in Attachment 2 in the attached background material. - Food efficiency:
- not examined
- Description (incidence and severity):
- not applicable
- Water consumption and compound intake (if drinking water study):
- not examined
- Description (incidence and severity):
- not applicable
- Ophthalmological findings:
- not examined
- Description (incidence and severity):
- not applicable
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- No toxicologically relevant differences were observed regarding hematology between control and treatment groups.
Statistically significant differences for red blood cell count and urea nitrogen were considered normal biological variation. The difference for red blood cell count was small; the differences for urea nitrogen were small, occurred in intermediate-dose males only, and were similar to findings observed before treatment was initiated.
Summarized results can be found in Attachment 3 in the attached background material. - Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- No differences were observed regarding clinical chemistry between control and treatment groups.
- Endocrine findings:
- not examined
- Description (incidence and severity):
- not applicable
- Urinalysis findings:
- not examined
- Description (incidence and severity):
- not applicable
- Behaviour (functional findings):
- not examined
- Description (incidence and severity):
- not applicable
- Immunological findings:
- not examined
- Description (incidence and severity):
- not applicable
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No toxicologically relevant differences were observed regarding organ weights between control and treatment groups.
Females of the 1000 mg/kg bw/day group showed increased absolute and relative kidney weights (< 15%), but these fell within the biological variation. Additionally, there were no macroscopic or microscopic findings in the kidneys of these animals correlating with the higher organ weights.
Summarized results can be found in Attachment 4 in the attached background material. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No toxicologically relevant differences were observed at necropsy between control and treatment groups.
- Neuropathological findings:
- not examined
- Description (incidence and severity):
- not applicable
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No toxicologically relevant differences were observed regarding histopathology between control and treatment groups.
- Histopathological findings: neoplastic:
- not examined
- Description (incidence and severity):
- not applicable
- Other effects:
- not examined
- Description (incidence and severity):
- not applicable
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- local
- Effect level:
- 30 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: The dermal irritation at this dose level was comparable to the vehicle control.
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- local
- Effect level:
- 300 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- dermal irritation
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects were observed up to the highest dose level.
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
The codes and abbreviations used in the tables are explained in Attachment 5 in the attached background material.
Applicant's summary and conclusion
- Conclusions:
- The study was conducted similar to OECD guideline 410 (1981) and under GLP. Under the conditions of the test, the test substance caused dermal irritation when applied dermally for three weeks to the intact skin of male and female New Zealand White rabbits, starting at 300 mg/kg bw/day. No systemic toxicity was observed. Thus, 30 mg/kg bw/day is regarded as the NOAEL for local skin effects and the NOAEL for systemic effects is 1000 mg/kg bw/day for males and females.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.